Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
本文未提供摘要，请点击“查看全文”查看完整内容。